MEDG Medgenics(Regs)

 
TIDMMEDG 
 
Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
 
                          Block Listing interim review 
 
                                                                     4 June 2009 
1. Name of company: 
 
   Medgenics, Inc. 
 
2. Name of scheme: 
 
   Warrants and Options under the Company's Share Incentive Schemes 
 
3. Period of return:           From                            To 
                          4 December 2008                 3 June 2009 
 
4. Number and class of securities not issued under the scheme at the beginning 
   of the period: 
 
   18,326,514 common shares of par value of US$0.01 each ("Common Shares") 
 
5. Number of securities issued under scheme during period: 
 
   11,692,499 
 
6. Balance under scheme of securities not yet issued at end of period: 
 
   6,634,015 Common Shares 
 
7. Number and class of securities originally admitted and the date of admission: 
 
   20,818,683 Common Shares admitted under the block admission on 4 December 2007. 
 
Following the above issues during the period the total number of Common Shares 
in issue is 118,420,694 .The percentage of shares not in public hands is 30.0 
per cent. There are no changes in the shareholders who hold more than three per 
cent. of the issued share capital as previously announced on 16 February 2009. 
 
 
For further information, contact: 
 
Medgenics, Inc.                                                Phone: +972 4 902 8900 
Dr. Andrew L. Pearlman 
 
Grayling Global (Financial PR, UK)                             Phone: +44 207 255 5406 
Jonathan Shillington or                                        jonathan.shillington@uk.grayling.com 
Alistair Scott 
 
Blomfield Corporate Finance Limited (Nominated Adviser)        Phone: +44 207 489 4500 
 
James Pinner or 
Alan MacKenzie 
 
SVS Securities plc (Broker)                                    Phone: +44 207 638 5600 
Ian Callaway 
 
United States contacts: 
 
Grayling Global (Investor Relations)                           Phone: +1 646 284 8472 
Leslie Wolf-Creutzfeldt                                        lwolf-creutzfeldt@hfgcg.com 
 
 
Grayling Global (Media Relations)                              Phone: +1 646 284 9455 
Ivette Almeida                                                 ialmeida@hfgcg.com 
 
 
 
NOTES TO EDITORS: 
 
Medgenics,  Inc.  is a clinical-stage biopharmaceutical company  developing  its 
unique  tissue-based  Biopump  platform technology to  provide  sustained-action 
protein therapy for the treatment of a range of chronic diseases. 
 
Medgenics currently has two products in development based on this technology: 
 
·    EPODURE - producing erythropoietin (EPO) to treat anemia 
·    INFRADURE - producing interferon-alpha (IFN-a) to treat hepatitis C 
 
The  Company  has  demonstrated  proof of principle  of  the  Biopump  treatment 
procedure in a clinical trial using a short-acting version of EPODURE in  anemic 
subjects.  The  Company announced positive initial results  in  its  Phase  I/II 
clinical  trial for its long-acting version of EPODURE, designed to produce  and 
deliver  a  therapeutic dose of EPO steadily for three to six  months  or  more, 
which  commenced  in August 2008. The Company plans to follow  with  a  clinical 
trial of INFRADURE. 
 
Medgenics  intends to develop its innovative products and bring them  to  market 
via  multiple  strategic partnerships with major pharmaceutical  and/or  medical 
device companies, starting with EPODURE and INFRADURE. 
 
Beyond these, Medgenics plans to develop and/or out-license a pipeline of future 
Biopump  products targeting the large and rapidly growing global protein therapy 
market, which is forecast to reach US $87 billion by 2010. Other potential areas 
include multiple sclerosis (interferon-a), haemophilia (Factor VIII), paediatric 
growth hormone deficiency (human growth hormone) and diabetes (insulin). 
 
Founded in 2000, Medgenics is a US-incorporated company with major operations in 
Misgav, Israel. Medgenics was admitted to AIM in December 2007 (AIM: MEDG). 
 
www.medgenics.com 
 
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS 
This  release contains forward-looking statements, which include all  statements 
other  than statements of historical fact, including (without limitation)  those 
regarding  the  Company's  financial  position,  business  strategy,  plans  and 
objectives  of  management  for future operations. These  statements  relate  to 
future   events,   prospects,   developments  and  strategies.   Forward-looking 
statements  are sometimes identified by their use of the terms and phrases  such 
as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, 
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or 
the  negative of such terms and other comparable terminology. All such  forward- 
looking  statements are based on current expectations and are subject  to  risks 
and  uncertainties. Should any of these risks or uncertainties  materialize,  or 
should  any  of  the Company's assumptions prove incorrect, actual  results  may 
differ  materially from those included within these forward-looking  statements. 
Accordingly,  no  undue  reliance  should be  placed  on  these  forward-looking 
statements,  which  speak  only  as  of the date  made.  The  Company  expressly 
disclaims  any obligation or undertaking to disseminate any updates or revisions 
to  any forward-looking statements contained herein to reflect any change in the 
Company's  expectations with regard thereto or any change in events,  conditions 
or  circumstances on which any such statements are based. As a result  of  these 
factors,  the  events described in the forward-looking statements  contained  in 
this release may not occur. 
 

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024